Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide versus Humalog Mix 25 for visceral fat reduction in non-overweight adults with type 2 diabetes and visceral obesity
ChiCTR-IPR-14005568Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of Nantong University
- Start
- Jan 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of exenatide and insulin lispro mix25 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Affiliated Hospital of Nantong University. Primary endpoint: Change in abdominal visceral adipose tissue area. Planned start Jan 2015; status: not yet recruiting.
02
Drugs
exenatideinsulin lispro mix25
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR-IPR-14005568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-14005568.